Cargando…

A TCR-like CAR Promotes Sensitive Antigen Recognition and Controlled T-cell Expansion Upon mRNA Vaccination

Chimeric antigen receptor (CAR) T cells are efficacious in patients with B-cell malignancies, while their activity is limited in patients with solid tumors. We developed a novel heterodimeric TCR-like CAR (TCAR) designed to achieve optimal chain pairing and integration into the T-cell CD3 signaling...

Descripción completa

Detalles Bibliográficos
Autores principales:	Birtel, Matthias, Voss, Ralf-Holger, Reinhard, Katharina, Rengstl, Benjamin, Ouchan, Yasmina, Michel, Kristina, Hayduk, Nina, Tillmann, Bodo, Becker, René, Suchan, Martin, Theobald, Matthias, Oehm, Petra, Türeci, Özlem, Sahin, Ugur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010320/ https://www.ncbi.nlm.nih.gov/pubmed/36923303 http://dx.doi.org/10.1158/2767-9764.CRC-21-0154

Ejemplares similares

Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies
por: Omokoko, Tana, et al.
Publicado: (2015)

An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells
por: Knies, Diana, et al.
Publicado: (2016)

TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential
por: Poorebrahim, Mansour, et al.
Publicado: (2021)

Racing for a SARS‐CoV‐2 vaccine
por: Türeci, Özlem, et al.
Publicado: (2021)

Joining Forces for Cancer Treatment: From “TCR versus CAR” to “TCR and CAR”
por: Teppert, Karin, et al.
Publicado: (2022)

Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain
por: Kuball, Jürgen, et al.
Publicado: (2009)

The Enigmatic Nature of the TCR-pMHC Interaction: Implications for CAR-T and TCR-T Engineering
por: Shevyrev, D. V., et al.
Publicado: (2022)

Selective activation of tumor growth-promoting Ca(2+ )channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2
por: Koslowski, Michael, et al.
Publicado: (2009)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

Targeting the tumor mutanome for personalized vaccination therapy
por: Kreiter, Sebastian, et al.
Publicado: (2012)

ATRT-17. CAR T CELL THERAPY TARGETING CLAUDIN-6 IS EFFECTIVE IN CELLULAR AND XENOGRAFT MODELS OF ATYPICAL TERATOID/RHABDOID TUMOR
por: Madsen, Peter, et al.
Publicado: (2023)

Challenges of CAR- and TCR-T cell–based therapy for chronic infections
por: Bertoletti, Antonio, et al.
Publicado: (2020)

A Costimulatory CAR Improves TCR-based Cancer Immunotherapy
por: Omer, Bilal, et al.
Publicado: (2022)

Molecular Characterization of Virus-induced Autoantibody Responses
por: Ludewig, Burkhard, et al.
Publicado: (2004)

NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells
por: Wagner, Meike, et al.
Publicado: (2013)

Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination
por: Vormehr, Mathias, et al.
Publicado: (2015)

Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma
por: Rohde, Christoph, et al.
Publicado: (2019)

Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020)
por: Ivica, Nikola A., et al.
Publicado: (2021)

Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer
por: Lordick, Florian, et al.
Publicado: (2023)

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
por: Mackensen, Andreas, et al.
Publicado: (2023)

Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
por: Lordick, Florian, et al.
Publicado: (2021)

CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins
por: Jost, Christian, et al.
Publicado: (2020)

TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens
por: Akatsuka, Yoshiki
Publicado: (2020)

Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells
por: Hiltensperger, Michael, et al.
Publicado: (2023)

Therapeutic targeting of PRAME with (mTCR)CAR T cells in acute myeloid leukemia
por: Kirkey, Danielle C., et al.
Publicado: (2022)

Pre-TCRα supports CD3-dependent reactivation and expansion of TCRα-deficient primary human T-cells
por: Galetto, Román, et al.
Publicado: (2014)

Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
por: MacLeod, Daniel T., et al.
Publicado: (2017)

mRNA therapeutics in cancer immunotherapy
por: Beck, Jan D., et al.
Publicado: (2021)

Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy
por: Zhu, Lichen, et al.
Publicado: (2020)

Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure
por: Wachsmann, Tassilo L. A., et al.
Publicado: (2022)

CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function
por: Sahillioglu, Ali Can, et al.
Publicado: (2021)

Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control
por: Cai, Yihua, et al.
Publicado: (2021)

Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4
por: Alsalloum, Alaa, et al.
Publicado: (2023)

Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer
por: Simon, Bianca, et al.
Publicado: (2019)

Pre-T cell receptor for improved expansion of TCR alpha disrupted T cells
por: Galetto, Roman, et al.
Publicado: (2013)

Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity
por: Omokoko, Tana A., et al.
Publicado: (2016)

Targeting the tumor vasculature with engineered cystine-knot miniproteins
por: Lui, Bonny Gaby, et al.
Publicado: (2020)

PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation
por: Roldán, Diana Barea, et al.
Publicado: (2020)

Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance
por: Füchsl, Franziska, et al.
Publicado: (2022)

Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
por: Sugita, Mayumi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fqjjt4tc86acmd0kmq4b3dscft